Cargando…

Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors

BACKGROUND: Sodium-glucose co-transporters (SGLT) inhibitors (SGLT2i) showed many beneficial effects at the cardiovascular level. Several mechanisms of action have been identified. However, no data on their capability to act via epigenetic mechanisms were reported. Therefore, this study aimed to inv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scisciola, Lucia, Taktaz, Fatemeh, Fontanella, Rosaria Anna, Pesapane, Ada, Surina, Cataldo, Vittoria, Ghosh, Puja, Franzese, Martina, Puocci, Armando, Paolisso, Pasquale, Rafaniello, Concetta, Marfella, Raffaele, Rizzo, Maria Rosaria, Barbato, Emanuele, Vanderheyden, Marc, Barbieri, Michelangela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896756/ https://www.ncbi.nlm.nih.gov/pubmed/36732760 http://dx.doi.org/10.1186/s12933-023-01754-2

Ejemplares similares

Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials
por: Scisciola, Lucia, et al.
Publicado: (2022)

Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists
por: Ghosh, Puja, et al.
Publicado: (2023)

Sarcopenia and Cognitive Function: Role of Myokines in Muscle Brain Cross-Talk
por: Scisciola, Lucia, et al.
Publicado: (2021)

Adiponectin Related Vascular and Cardiac Benefits in Obesity: Is There a Role for an Epigenetically Regulated Mechanism?
por: Fontanella, Rosaria Anna, et al.
Publicado: (2021)

miR-21 in Human Cardiomyopathies
por: Surina,, et al.
Publicado: (2021)

Corrigendum: miR-21 in Human Cardiomyopathies
por: Surina,, et al.
Publicado: (2022)

Potential Role of Lisinopril in Reducing Atherosclerotic Risk: Evidence of an Antioxidant Effect in Human Cardiomyocytes Cell Line
por: Scisciola, Lucia, et al.
Publicado: (2022)

Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition
por: Rizzo, Maria Rosaria, et al.
Publicado: (2012)

Response to Comment on: Rizzo et al. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of Dipeptidyl Peptidase-IV Inhibition. Diabetes Care 2012;35:2076–2082
por: Rizzo, Maria Rosaria, et al.
Publicado: (2013)

Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
por: Mascolo, Annamaria, et al.
Publicado: (2023)

Cardiac Resynchronization Therapy Outcomes in Type 2 Diabetic Patients: Role of MicroRNA Changes
por: Sardu, Celestino, et al.
Publicado: (2016)

Association of Genetic Variation in Adaptor Protein APPL1/APPL2 Loci with Non-Alcoholic Fatty Liver Disease
por: Barbieri, Michelangela, et al.
Publicado: (2013)

Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
por: Mascolo, Annamaria, et al.
Publicado: (2022)

Awaking Blood Pressure Surge and Progression to Microalbuminuria in Type 2 Normotensive Diabetic Patients
por: Barbieri, Michelangela, et al.
Publicado: (2016)

Mediterranean Diet, Telomere Maintenance and Health Status among Elderly
por: Boccardi, Virginia, et al.
Publicado: (2013)

Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry
por: Paolisso, Pasquale, et al.
Publicado: (2023)

Relationships Between Daily Acute Glucose Fluctuations and Cognitive Performance Among Aged Type 2 Diabetic Patients
por: Rizzo, Maria Rosaria, et al.
Publicado: (2010)

SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes
por: Marfella, Raffaele, et al.
Publicado: (2023)

Reply to SGLT-2 inhibitors: Post-infarction interventional effects
por: Paolisso, Pasquale, et al.
Publicado: (2023)

Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes
por: Sardu, Celestino, et al.
Publicado: (2017)

Bariatric Surgery Reduces Oxidative Stress by Blunting 24-h Acute Glucose Fluctuations in Type 2 Diabetic Obese Patients
por: Marfella, Raffaele, et al.
Publicado: (2010)

Editorial: Clinical prospective of SGLT2 inhibitors in atherosclerosis
por: Capuano, Annalisa, et al.
Publicado: (2022)

In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study
por: Cesaro, Arturo, et al.
Publicado: (2022)

Cardiac electrophysiological alterations and clinical response in cardiac resynchronization therapy with a defibrillator treated patients affected by metabolic syndrome
por: Sardu, Celestino, et al.
Publicado: (2017)

Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate
por: Sardu, Celestino, et al.
Publicado: (2018)

ELectrophysiological mechanisms underlying the Inhibitory CArdiac syncope without asystolic significant pause: Therapeutic and prognostic implications. The ELICA randomized trial
por: Sardu, Celestino, et al.
Publicado: (2018)

SGLT2 and cancer
por: Wright, Ernest M.
Publicado: (2020)

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
por: Salvatore, Teresa, et al.
Publicado: (2022)

Serum adiponectin levels are associated with worse cognitive function in postmenopausal women
por: De Franciscis, Pasquale, et al.
Publicado: (2017)

Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
por: D'Onofrio, Nunzia, et al.
Publicado: (2021)

SARS-COV-2 colonizes coronary thrombus and impairs heart microcirculation bed in asymptomatic SARS-CoV-2 positive subjects with acute myocardial infarction
por: Marfella, Raffaele, et al.
Publicado: (2021)

Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
por: Ghezzi, Chiara, et al.
Publicado: (2018)

Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Pericoronary fat inflammation and Major Adverse Cardiac Events (MACE) in prediabetic patients with acute myocardial infarction: effects of metformin
por: Sardu, Celestino, et al.
Publicado: (2019)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
por: Zhang, Yu, et al.
Publicado: (2023)

Hyperglycaemia on admission to hospital and COVID-19
por: Sardu, Celestino, et al.
Publicado: (2020)

Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?
por: Sardu, Celestino, et al.
Publicado: (2020)

Atherosclerotic Plaque Fissuration and Clinical Outcomes in Pre-Diabetics vs. Normoglycemics Patients Affected by Asymptomatic Significant Carotid Artery Stenosis at 2 Years of Follow-Up: Role of microRNAs Modulation: The ATIMIR Study
por: Sardu, Celestino, et al.
Publicado: (2021)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
por: Sayour, Alex Ali, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vrpl4mkmiohbbjubhhcbfvi56j